GenoMed Formalizes Alliance with Renowned Disease Management Consulting Firms.

Business Editors/Health & Medical Writers

SARASOTA, Fla.--(BUSINESS WIRE)--Jan. 9, 2002

GenoMed, Inc., ("the Company" or "GenoMed") (Pink Sheets:GMED) a St. Louis-based medical genomics biotechnology company, today announced that it has finalized an Agreement with Better Health Technologies, LLC of Boise, Idaho, in collaboration with Medical Outcomes Management, Inc., health care management, technology consulting and business development companies that focus on disease management and e-health.

Better Health Technologies (BHT) and Medical Outcomes Management (MOM) will assist GenoMed in finding partners and initial customers for treatment algorithms developed by the Company. The treatment algorithms to be marketed are the subject of Provisional Patent Applications filed by the Company with the United States Patent and Trademark Office.

David W. Moskowitz, GenoMed's Chairman and Chief Medical Officer, stated, "Better Health Technologies (BHT) and Medical Outcomes Management (MOM) are well known and respected organizations within the disease management field. They have worked with a broad range of companies involved with chronic disease management and Internet care, including disease management, pharmaceutical, Internet health companies, hospitals, health plans, state agencies, and physician groups. BHT's and MOM's expertise in business strategy, business and clinical models, and partnership development will be important to GenoMed over the coming months." Dr. Moskowitz added, "The algorithms we've developed have the potential to dramatically reduce healthcare costs and improve outcomes in targeted diseases by helping patients and their care providers manage chronic diseases through applications of medical genomics."

About GenoMed

GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.

About Better Health Technologies and Medical Outcomes Management

Vince Kuraitis JD, MBA is Principal of Better Health Technologies, LLC, and has 19 years diverse experience in health care business development, operations, management consulting, and marketing. His experience spans over 90 different health care organizations. Vince's prior work experience includes: President, Health Choice; Vice President of Corporate Development and Operations for a regional health system; Regional Director of Marketing for 15 hospitals with a for-profit national hospital management company; and consultant with a national health care management consulting firm. Vince's education includes MBA and JD degrees from UCLA, and a BS degree in business administration from USC.

Alan F. Kaul, R.Ph., M.S., M.B.A., F.C.C.P., President of Medical Outcomes Management, Inc., will also serve as a clinical and marketing consultant to GenoMed in collaboration with BHT. Mr. Kaul has more than 30 years of health care management, consulting, and operational experience including evaluating, developing and implementing broad-reaching health care programs such as: disease management, drug-utilization evaluation, and prescribing modification based upon educational outreach principles. Mr. Kaul has served as Health Care Consultant at The Lewin Group (Washington, DC), Vice President for Clinical and Quality Assurance Services at the Homecare Division of National Medical Care and, Director of Pharmacy Services at Brigham and Women's Hospital. He has authored more than 70 publications in the scientific literature and was elected to Fellowship in the American College of Clinical Pharmacy. Mr. Kaul holds an M.B.A. from Suffolk University and an M.S. in Pharmacology and B.S. in Pharmacy from Northeastern University. Mr. Kaul serves on the Board of Directors of The Institute of Management Consultants, New England (IMCNE) and was formerly President of the Health Care Consultants of New England. Mr. Kaul also serves on the Strategy Planning Group for the Secondary Prevention of Coronary Heart Disease of the American Heart Association, New England Affiliate.

For additional information please visit http://www.genomedics.com and/or contact Craig Hall at 941/366-6677 or email at [e-mail] to receive a GenoMed investor kit.

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the beneficial nature of the share exchange. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties. Among other things, competition from existing or new competitors will impact our business; our research and development is subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.